113 related articles for article (PubMed ID: 21690062)
1. [Expressions of p53 pathway genes and EZH2 in undifferentiated nasopharyngeal carcinoma].
Liu XD; Ji MF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1029-33. PubMed ID: 21690062
[TBL] [Abstract][Full Text] [Related]
2. FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma.
Shu XS; Li L; Ji M; Cheng Y; Ying J; Fan Y; Zhong L; Liu X; Tsao SW; Chan AT; Tao Q
Carcinogenesis; 2013 Sep; 34(9):1984-93. PubMed ID: 23677067
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
[TBL] [Abstract][Full Text] [Related]
4. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?
Crook T; Nicholls JM; Brooks L; O'Nions J; Allday MJ
Oncogene; 2000 Jul; 19(30):3439-44. PubMed ID: 10918601
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin promotes EZH2 expression and tumor progression in nasopharyngeal carcinoma.
Ma R; Luo X; Feng S; Li J; Fan Y; Wen W; Li H
ORL J Otorhinolaryngol Relat Spec; 2014; 76(5):273-81. PubMed ID: 25471249
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
8. [Effects of enhancer of zeste homolog (EZH2) downregulation on the proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanisms].
LIANG BJ; LI XP; LU J; LIN SX; LIU X; LI G; ZHANG B; WANG L; LUO HN; WAN RQ; TIAN WD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 47(4):298-304. PubMed ID: 22800347
[TBL] [Abstract][Full Text] [Related]
9. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
10. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
Zhang H; Chen S; Niu G; Jiang H; Yao S
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
[TBL] [Abstract][Full Text] [Related]
12. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells.
Cai K; Wan Y; Sun G; Shi L; Bao X; Wang Z
Oncol Rep; 2012 Dec; 28(6):2101-6. PubMed ID: 22972404
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of GSK 3β activity is associated with excessive EZH2 expression and enhanced tumour invasion in nasopharyngeal carcinoma.
Ma R; Wei Y; Huang X; Fu R; Luo X; Zhu X; Lei W; Fang J; Li H; Wen W
PLoS One; 2013; 8(7):e68614. PubMed ID: 23874688
[TBL] [Abstract][Full Text] [Related]
14. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.
Huang Y; Wang X; Niu X; Wang X; Jiang R; Xu T; Liu Y; Liang L; Ou X; Xing X; Li W; Hu C
Mol Carcinog; 2017 Feb; 56(2):447-463. PubMed ID: 27253463
[TBL] [Abstract][Full Text] [Related]
15. EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma.
Lu J; Zhao FP; Peng Z; Zhang MW; Lin SX; Liang BJ; Zhang B; Liu X; Wang L; Li G; Tian WD; Peng Y; He ML; Li XP
Oncotarget; 2014 Nov; 5(22):11319-32. PubMed ID: 25237831
[TBL] [Abstract][Full Text] [Related]
16. Eudesmin exerts antitumor effects by down-regulating EZH2 expression in nasopharyngeal carcinoma cells.
Yu M; Li Y; Li M; Lu D
Chem Biol Interact; 2019 Jul; 307():51-57. PubMed ID: 31026422
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
[TBL] [Abstract][Full Text] [Related]
18. [MDM2 gene expression in nasopharyngeal carcinoma and its relationship with p53 protein expression and EB virus latent infection].
Luo JL; Xiao JY; Tian YQ; Zhao SP; Liu JW; Tao ZD
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Nov; 14(11):507-9. PubMed ID: 12563945
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
20. Expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1), p16 and p53 proteins in nonendemic nasopharyngeal carcinoma (NPC): a clinicopathological study.
Rosales-Pérez S; Cano-Valdez AM; Flores-Balcázar CH; Guedea-Edo F; Lino-Silva LS; Lozano-Borbalas A; Navarro-Martín A; Poitevin-Chacón A
Arch Med Res; 2014 Apr; 45(3):229-36. PubMed ID: 24606815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
